Safe Harbor Statement

This presentation may contain forward-looking statements that involve risks and uncertainties, including our financial outlook and guidance for fiscal 2018 and expectations regarding the development and commercialization of new products. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are (i) challenges inherent in developing, manufacturing, and launching new products and services, including expanding manufacturing operations and reliance on third-party suppliers for critical components; (ii) the timing and mix of customer orders among our products and services; (iii) the impact of recently launched or pre-announced products and services on existing products and services; (iv) our ability to further develop and commercialize our instruments and consumables and to deploy new products, services, and applications, and expand the markets for our technology platforms; (v) our ability to manufacture robust instrumentation and consumables; (vi) the success of products and services competitive with our own; (vii) our ability to successfully identify and integrate acquired technologies, products, or businesses; (viii) our expectations and beliefs regarding future conduct and growth of the business and the markets in which we operate; and (ix) the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts’ expectations, or to provide interim reports or updates on the progress of the current quarter.
Illumina at a Glance

Company

- April 1998 Founded
- July 2000 IPO
- Francis deSouza President and CEO
- San Diego, CA Headquarters
- +6,200 Employees
- 22 Offices Globally

Financials

- $2.75B Revenue
- 15% Revenue growth YoY
- $~42B Market Cap as of June 12, 2018

Our Mission

To improve human health by unlocking the power of the genome
DNA Analysis is Potentially Transformative
DNA Analysis is Potentially Transformative

- Personalized Medicine
- Predispositions & Symptoms
- Family Planning
- Lifestyle Choices
Why Genomics Matters: Emma’s Costly Diagnostic Odyssey*

Lagging Milestones.
- Misdiagnosed with Guillain-Barre syndrome.
- 2 x ICU Visits.
- Continued Decline.

Genetic testing leads to diagnosis of Riboflavin Transporter Deficiency.
- Treated with Vitamin B2

19 Months
21 months
28 months
Today

Walking, but loss of hearing, use of hands and arms, & limited swallowing.

Earlier testing and treatment could have dramatically reduced neurological damage

* Patient’s name has been changed to protect her identity. The case details are as reported, but the images are for illustration only.
Why Genomics Matters: Marisa’s Unexpected NIPT Finding

* Patient’s name has been changed to protect her identity. The case details are as reported, but the images are for illustration only.

Routine NIPT test

4 Months

6 months

8 months

Today

Additional testing led to cancer diagnosis for Mom

Cancerous nodules shrinking

Baby Oliver* delivered so Mom can begin treatment

Genomic testing led to earlier diagnosis of cancer
<table>
<thead>
<tr>
<th>Cost Per Genome</th>
<th>Event Description</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>$3,000,000,000</td>
<td>Human Genome Project</td>
<td>2003</td>
</tr>
<tr>
<td>$20,000,000</td>
<td>1st individual genome</td>
<td>2006</td>
</tr>
<tr>
<td>$2,000,000</td>
<td>1st NGS Genome</td>
<td>2007</td>
</tr>
<tr>
<td>$200,000</td>
<td>1st 30x genome</td>
<td>2008</td>
</tr>
<tr>
<td>$10,000</td>
<td>1st sub-10K genome</td>
<td>2010</td>
</tr>
<tr>
<td>$1,000</td>
<td>1st $1,000 genome</td>
<td>2014</td>
</tr>
</tbody>
</table>

**Launched the NovaSeq*** | 2017

* A new sequencing architecture expected one day to enable a $100 genome.
Installed Base >11,000: Sequencing Power for Every Scale

>90% of all sequencing performed has been generated on Illumina technology

Decreasing price per GB
Increasing system price & output

Shipping Soon
iSeq™

~600
MiniSeq™

~6,000
MiSeq™

~2,400
NextSeq™

~2,300
HiSeq™

~285
NovaSeq™
Robust Sequencing Consumable Revenue Growth

- $0
- $200
- $400
- $600
- $800
- $1,000
- $1,200
- $1,400
- $1,600

- 2007
- 2008
- 2009
- 2010
- 2011
- 2012
- 2013
- 2014
- 2015
- 2016
- 2017

28% CAGR
Focus Areas

- Non-Invasive Prenatal Testing (NIPT)
- Rare and Undiagnosed Disease (RUGD)
- Oncology
- Population Genomics
- Consumer Genomics
Non-Invasive Prenatal Testing (NIPT)

World bank population data, World bank birth rate (June 2017)
Rare and Inherited Disease

250M RUGD Patients Worldwide

Average 5–7 Years to Diagnosis in the US & UK

Genetic diseases are responsible for:

- 45–51% NICU deaths
- 19% PICU deaths
- 50% admissions to pediatric long-term care
- 60% end-of-life admissions
- 30% of children with rare disease will not live to see their fifth birthday
<table>
<thead>
<tr>
<th>Focused Panels</th>
<th>Mid-Sized Panels</th>
<th>Comprehensive Solutions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Targeted therapies</strong></td>
<td><strong>Targeted therapies + Immuno/therapies (IO) + ctDNA</strong></td>
<td><strong>Targeted therapies + IO + ctDNA</strong></td>
</tr>
<tr>
<td>5–50 Genes</td>
<td>50–500 Gene panels</td>
<td>500+ Genes, WES, WTS, WGS</td>
</tr>
<tr>
<td>Regional Hospital</td>
<td>Reference Laboratory</td>
<td>Reference Laboratory</td>
</tr>
<tr>
<td><strong>TST15</strong></td>
<td></td>
<td><strong>Academic Medical Center</strong></td>
</tr>
<tr>
<td><strong>AmpliSeq for ILMN</strong></td>
<td><strong>TruSight Tumor 170</strong>&lt;sup&gt;**&lt;/sup&gt; <strong>TS Oncology 500</strong>&lt;sup&gt;*&lt;/sup&gt;</td>
<td><strong>TS Oncology 500</strong>&lt;sup&gt;*&lt;/sup&gt; <strong>Whole Exome Sequencing</strong> <strong>Whole Transcriptome Seq</strong> <strong>Whole Genome Sequencing</strong></td>
</tr>
</tbody>
</table>

*TruSight Oncology 500 (TSO 500) is in development; **TruSight Tumor 170 (TST 170) is available as an RUO and IUO.
Consumer Genomics Inflecting

>12M Samples
Genotyped or Sequenced to Date
Population Genomics

Genomics England
100,000 genomes

All of Us
1 million participants

MVP
1 million participants

France
~235,000 genomes

Canada
United States
United Kingdom
France
Spain
Norway
Finland
Denmark
Switzerland
Italy
Turkey
Israel
South Korea
Japan
China
Singapore
Australia
Delivering Shareholder Value

Strong financials and disciplined capital allocation

History of robust revenue growth

<table>
<thead>
<tr>
<th>Year</th>
<th>Revenue ($ millions)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2007</td>
<td>$367</td>
</tr>
<tr>
<td>2008</td>
<td>$159</td>
</tr>
<tr>
<td>2009</td>
<td>$265</td>
</tr>
<tr>
<td>2010</td>
<td>$327</td>
</tr>
<tr>
<td>2011</td>
<td>$244</td>
</tr>
<tr>
<td>2012</td>
<td>$364</td>
</tr>
<tr>
<td>2013</td>
<td>$522</td>
</tr>
<tr>
<td>2014</td>
<td>$643</td>
</tr>
<tr>
<td>2015</td>
<td>$519</td>
</tr>
<tr>
<td>2016</td>
<td>$565</td>
</tr>
<tr>
<td>2017</td>
<td>$2,752</td>
</tr>
</tbody>
</table>

22% CAGR

Free cash flow growth

<table>
<thead>
<tr>
<th>Year</th>
<th>Free Cash Flow ($ millions)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2007</td>
<td>$52</td>
</tr>
<tr>
<td>2008</td>
<td>$47</td>
</tr>
<tr>
<td>2009</td>
<td>$159</td>
</tr>
<tr>
<td>2010</td>
<td>$265</td>
</tr>
<tr>
<td>2011</td>
<td>$327</td>
</tr>
<tr>
<td>2012</td>
<td>$244</td>
</tr>
<tr>
<td>2013</td>
<td>$364</td>
</tr>
<tr>
<td>2014</td>
<td>$522</td>
</tr>
<tr>
<td>2015</td>
<td>$643</td>
</tr>
<tr>
<td>2016</td>
<td>$519</td>
</tr>
<tr>
<td>2017</td>
<td>$565</td>
</tr>
</tbody>
</table>

Strong operating leverage

<table>
<thead>
<tr>
<th>Year</th>
<th>Margin (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2007</td>
<td>16.4%</td>
</tr>
<tr>
<td>2017</td>
<td>25.0%</td>
</tr>
</tbody>
</table>

+860 bps

Disciplined capital allocation

- Strategic M&A
- Internal Investments
- Stock Buybacks
- Debt Management

1. Operating margin; adjusted non-GAAP as a percentage of revenue
2018 Guidance

- **2014**: $1,861
- **2015**: $2,220
- **2016**: $2,398
- **2017**: $2,752
- **2018**: ~$3,179

**2018 Guidance:**
- **GAAP EPS**: $4.45 - $4.55
- **Non-GAAP EPS**: $4.75 - $4.85

**YoY Growth**: 15% - 16%
Innovation Expanding Market Opportunities

- Reproductive Health
- Oncology
- Population Sequencing
- Research
- Complex Disease
- Consumer
- Infectious Disease
- Public Health
- Agriculture
- Genetic Health
- BioPharm

Questions? Contact Illumina Investor Relations | ir@illumina.com | (408) 594-9328
Illumina, Inc.
Reconciliation of Non-GAAP Financial Guidance

Our future performance and financial results are subject to risks and uncertainties, and actual results could differ materially from the guidance set forth below. Some of the factors that could affect our financial results are stated above in this press release. More information on potential factors that could affect our financial results is included from time to time in the public reports filed with the Securities and Exchange Commission, including Form 10-K for the fiscal year ended December 31, 2017 filed with the SEC on February 12, 2018, and Form 10-Q for the fiscal quarter ended April 1, 2018. We assume no obligation to update any forward-looking statements or information.

<table>
<thead>
<tr>
<th>GAAP diluted earnings per share attributable to Illumina stockholders</th>
<th>Fiscal Year 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amortization of acquired intangible assets</td>
<td>$4.45 - $4.55</td>
</tr>
<tr>
<td>Non-cash interest expense (a)</td>
<td>0.24</td>
</tr>
<tr>
<td>Strategic investment related gains (b)</td>
<td>(0.05)</td>
</tr>
<tr>
<td>Restructuring (c)</td>
<td>0.03</td>
</tr>
<tr>
<td>Incremental non-GAAP tax expense (d)</td>
<td>(0.11)</td>
</tr>
<tr>
<td>Excess tax benefits from share-based compensation (e)</td>
<td>(0.02)</td>
</tr>
<tr>
<td>Non-GAAP diluted earnings per share attributable to Illumina stockholders</td>
<td>$4.75 - $4.85</td>
</tr>
</tbody>
</table>

(a) Non-cash interest expense is calculated in accordance with the authoritative accounting guidance for convertible debt instruments that may be settled in cash.

(b) Amount consists primarily of mark-to-market adjustments from our strategic investments.

(c) Amount consists primarily of employee severance and retention costs related to the restructuring that occurred in Q1 2018 and Q4 2017.

(d) Incremental non-GAAP tax expense reflects the tax impact related to the non-GAAP adjustments listed above.

(e) Amount represents tax deductions taken in excess of stock compensation cost.